Diagnosed with small-cell lung cancer at 28, Montessa Lee has defied the odds for nearly 20 years, surviving a disease with a ...

According to the NCCN Guidelines for metastatic lung cancer, standard therapies remain valuable, but they are no longer sufficient on their own. This is why molecular profiling, targeted therapy, and ...

Phase 2 data presented at the 40th Society for Immunotherapy of Cancer (SITC) Annual Meeting show deep and durable tumor regressions in heavily pre-treated melanoma patients, with a mild safety ...

Maida Mangiameli, 75, has defied the odds by surviving over seven years with small-cell lung cancer—a disease with a ...

October brought several updates in the lung cancer field, ranging from notable trial results to patient-centered perspectives ...

Dr. Mariano Provencio says many patients still face recurrence after lung cancer surgery and perioperative treatment aims to ...

Synthekine Inc., an engineered cytokine therapeutics company, today announced positive initial results from a Phase 1a/1b clinical trial of STK-012 in first-line, PD-L1 negative nonsquamous (NSQ) ...

Akeso has data showing ivonescimab can extend the lives of patients with previously treated EGFR-mutated non-small cell lung ...

Therapeutics, Inc., a commercial-stage medical technology company pioneering pulsed electric field (PEF) therapies for oncology and chronic lung disease, today announced the online publication of ...

Studies reveal how the Lunit SCOPE® suite identifies immunotherapy-responsive subtypes, standardizes immune phenotyping, and accelerates antibody-based target discovery ...

As the race to develop oncology bispecifics heats up, Pfizer has offered a first look at its strategy to dethrone Keytruda and establish its ...

A panelist discusses how novel bispecifics and ADCs signal a more hopeful future for ES-SCLC management. A panelist discusses how the therapeutic landscape of extensive-stage small cell lung cancer ...